AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6412384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30913305 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fractionation radiotherapy concurrent with cisplatin (RTOG-0129)
Number of subjects: 547
Study 30913305 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy concurrent with cisplatin (RTOG-0522)
Number of subjects: 547
Study 30913305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and accelerated fractionation with or without cetuximab (RTOG-0522)
Number of subjects: 547
Study 30217172 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN β‐1a 22 μg
Number of subjects: 560
Study 30217172 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN β‐1a 44 μg
Number of subjects: 560
Study 30217172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 27142721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehearsal (CR)
Number of subjects: 10
Study 27142721 — intervention group
Group type: COMPARATOR
Intervention: Physical Rehearsal (PR)
Number of subjects: 10
Study 24979287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad practice
Number of subjects: 84
Study 24979287 — intervention group
Group type: COMPARATOR
Intervention: Individual practice
Number of subjects: 84
Study 22441345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 822
Study 22441345 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 40 mg
Number of subjects: 822
Study 20656351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections for CNV
Number of subjects: 24
Study 17301739 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 12
Study 17301739 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 12
Study 15231557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam (4 mg)
Number of subjects: 200
Study 15231557 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (10 mg) plus promethazine (25-50 mg mix)
Number of subjects: 200
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625/MPA 2.5 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 2.5 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 1.5 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3/MPA 1.5 mg/day
Number of subjects: 2673
Study 11438315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study 9849704 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy (control group)
Number of subjects: 18
Study 9849704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclamptic state
Number of subjects: 18
Study 7973211 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2570283 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 7
Study 164128 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) with transitional day care available
Number of subjects: 175
Study 164128 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization without day care
Number of subjects: 175
Study 164128 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient care (discharge at the therapist's discretion)
Number of subjects: 175
Study 30249694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Number of subjects: 69
Study 27833860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (2%) with adrenaline (1:100,000)
Number of subjects: 0
Study 27833860 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine (2%) injection with topical adrenaline (1:10,000)
Number of subjects: 0
Study 24730575 — intervention group
Group type: EXPERIMENTAL
Intervention: FACTSHEETS - a series of four electronic factsheets
Number of subjects: 222
Study 24730575 — intervention group
Group type: EXPERIMENTAL
Intervention: HPE - an online interactive health promotion website
Number of subjects: 222
Study 24730575 — intervention group
Group type: EXPERIMENTAL
Intervention: HPE + MI - the online health promotion website plus two 30-minute calls with a trained motivational interviewer
Number of subjects: 222
Study 23228097 — intervention group
Group type: COMPARATOR
Intervention: HALDN
Number of subjects: 100
Study 23228097 — intervention group
Group type: EXPERIMENTAL
Intervention: TPLDN
Number of subjects: 100
Study 19952841 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (decrease caloric intake and increase physical activity levels)
Number of subjects: 170
Study 18647281 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of environmental music
Number of subjects: 40
Study 18647281 — intervention group
Group type: COMPARATOR
Intervention: Usual level of environmental music
Number of subjects: 40
Study 15610370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (single dose)
Number of subjects: 133
Study 15610370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (multiple doses)
Number of subjects: 133
Study 15610370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (single and multiple doses)
Number of subjects: 133
Study 15610370 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo (single dose)
Number of subjects: 133
Study 15610370 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo (multiple doses)
Number of subjects: 133
Study 11581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/d for first 5 days, then 5 g/d)
Number of subjects: 25
Study 11581550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium phosphate monohydrate)
Number of subjects: 25
Study 11581550 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 25
Study 9831573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient enriched preterm formula as sole diet
Number of subjects: 424
Study 9831573 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 424
Study 7815378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive induction
Number of subjects: 60
Study 7815378 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral induction
Number of subjects: 60
Study 7815378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 2803681 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12
Study 2803681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4393372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide 3-6 mg daily
Number of subjects: 290
Study 4393372 — intervention group
Group type: EXPERIMENTAL
Intervention: BC105
Number of subjects: 290
Study 4393372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methdilazine
Number of subjects: 290
Study 4393372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 290
Study 4393372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergol carbamide maleate
Number of subjects: 290
Study 4393372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 31945659 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anaesthesia (IA) with 0.2% ropivacaine (RPV) and FNT 50 μg
Number of subjects: 94
Study 31945659 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anaesthesia (IA) with 0.2% bupivacaine (BPV) and FNT 50 μg
Number of subjects: 94
Study 31945659 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 94
Study 30907141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 30907141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 0
Study 30907141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 0
Study 30907141 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0
Study 28493877 — intervention group
Group type: EXPERIMENTAL
Intervention: AnapnoGuard™ 100 system (AG)
Number of subjects: 60
Study 25711974 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, telephone‐based, interactive voice response (IVR) intervention, called twice weekly
Number of subjects: 60
Study 25711974 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, telephone‐based, interactive voice response (IVR) intervention
Number of subjects: 60
Study 25711974 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study 24238317 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care serum ketone measurement (beta-hydroxybutyrate)
Number of subjects: 188
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine + dexamphetamine
Number of subjects: 12
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine + dexamphetamine
Number of subjects: 12
Study 21485398 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 21485398 — intervention group
Group type: COMPARATOR
Intervention: non-immersion control with no drug
Number of subjects: 12
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: meclizine
Number of subjects: 12
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 12
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine
Number of subjects: 12
Study 21485398 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine + caffeine
Number of subjects: 12
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmodular components
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene step-cut implants
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-backed nonmodular fixed-bearing implants
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular fixed-bearing implants
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmodular all-polyethylene step-cut devices
Number of subjects: 50
Study 19751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure modes
Number of subjects: 50
Study 16981140 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA)
Number of subjects: 526
Study 16981140 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA
Number of subjects: 526
Study 16981140 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol plus MPA
Number of subjects: 526
Study 16981140 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 526
Study 15287931 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily plus a mildly reduced-calorie diet
Number of subjects: 1004
Study 15287931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study 11389505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin
Number of subjects: 0
Study 11389505 — intervention group
Group type: COMPARATOR
Intervention: Glycopeptide (vancomycin or teicoplanin) plus gentamicin
Number of subjects: 0
Study 9430132 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to organic solvents
Number of subjects: 320
Study 9430132 — intervention group
Group type: COMPARATOR
Intervention: Control group (referents)
Number of subjects: 320
Study 8215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 125,000 U
Number of subjects: 134
Study 8215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 250,000 U
Number of subjects: 134
Study 8215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 500,000 U
Number of subjects: 134
Study 8215644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 134
Study 3684128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (N = 44)
Number of subjects: 89
Study 3684128 — intervention group
Group type: COMPARATOR
Intervention: Nonbladder training (N = 45)
Number of subjects: 89
Study 28601957 — intervention group
Group type: COMPARATOR
Intervention: Coping skills intervention
Number of subjects: 50
Study 28601957 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer helping + coping skills intervention
Number of subjects: 50
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive Control (Food restriction)
Number of subjects: 160
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive Control (Pressure-to-eat)
Number of subjects: 160
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Directive Control (Obesogenic home food environment)
Number of subjects: 160
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Directive Control (Parental role modeling of healthful eating)
Number of subjects: 160
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive Control
Number of subjects: 160
Study 27486926 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Directive Control
Number of subjects: 160
Study 24748301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber-reinforced post (FRP)
Number of subjects: 40
Study 24748301 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel parapost (PP)
Number of subjects: 40
Study 21248612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid modified‐immediate‐release (MIR) 1.3 g (2 650‐mg tablets)
Number of subjects: 72
Study 21248612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid delayed‐release (DR) 1.3 g (2 650‐mg tablets)
Number of subjects: 72
Study 21248612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid MIR 1.3 g dosed every 8 hours for 5 days
Number of subjects: 72
Study 21248612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid DR 1.3 g
Number of subjects: 72
Study 20337841 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 196
Study 20337841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment (Induction Chemotherapy and Chemoradiation)
Number of subjects: 196
Study 18692658 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Advantage Supra
Number of subjects: 80
Study 18692658 — intervention group
Group type: COMPARATOR
Intervention: St Jude Medical Regent
Number of subjects: 80
Study 18692658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 15188756 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/kg)
Number of subjects: 0
Study 11719116 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance‐compensated biphasic truncated exponential (ICBTE) AED
Number of subjects: 338
Study 11719116 — intervention group
Group type: COMPARATOR
Intervention: Monophasic truncated exponential (MTE) AED
Number of subjects: 338
Study 11719116 — intervention group
Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) AED
Number of subjects: 338
Study 11719116 — intervention group
Group type: COMPARATOR
Intervention: All waveforms (ICBTE, MTE, MDS)
Number of subjects: 338
Study 8985227 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine plus quinine
Number of subjects: 39
Study 8985227 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus quinine
Number of subjects: 39
Study 8985227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8985227 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Number of subjects: 39
Study 8985227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 7963426 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 73
Study 7963426 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 73
Study 3630808 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically-based control program with advice to quit from physicians and nurses
Number of subjects: 250
Study 30415407 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day)
Number of subjects: 60
Study 30415407 — intervention group
Group type: COMPARATOR
Intervention: Vonoprazan (20 mg/day)
Number of subjects: 60
Study 30125336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine contraception
Number of subjects: 748
Study 30125336 — intervention group
Group type: COMPARATOR
Intervention: Hormonal contraceptive methods
Number of subjects: 748
Study 30125336 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 748
Study 26234336 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 15
Study 26234336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24299914 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed training documentation on standardized BP measurement (group I: 14 doctors)
Number of subjects: 257
Study 24299914 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about high BP (group II: 12 doctors)
Number of subjects: 257
Study 24299914 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements by PCPs
Number of subjects: 257
Study 24299914 — intervention group
Group type: COMPARATOR
Intervention: Misdiagnosis rates
Number of subjects: 257
Study 22316839 — intervention group
Group type: EXPERIMENTAL
Intervention: School based exercise program (twice a week for six weeks, 50 minutes per session)
Number of subjects: 58
Study 22316839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 20430576 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs registered in a trial registry
Number of subjects: 148
Study 20430576 — intervention group
Group type: COMPARATOR
Intervention: RCTs not registered in a trial registry
Number of subjects: 148
Study 20430576 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to CONSORT items
Number of subjects: 148
Study 20430576 — intervention group
Group type: EXPERIMENTAL
Intervention: All RCTs
Number of subjects: 148
Study 20430576 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs
Number of subjects: 148
Study 17692991 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40 kDa) plus ribavirin for 72 weeks
Number of subjects: 0
Study 17692991 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 0
Study 15882220 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% dexibuprofen mouth rinse
Number of subjects: 24
Study 15882220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11277962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily for 6 weeks
Number of subjects: 190
Study 11277962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 9252849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (0.5 microgram twice a day for 5 days) + calcium carbonate (1,500 mg/day) + carbocalcitonin (40 UMRC intramuscularly three times weekly)
Number of subjects: 59
Study 9252849 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study 8503418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal recombinant human erythropoietin (Epo) at 99.1 U/kg
Number of subjects: 8
Study 8503418 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (Epo)
Number of subjects: 8
Study 8503418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (Epo)
Number of subjects: 8
Study 3606167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water iontophoresis
Number of subjects: 18
Study 3606167 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated hand)
Number of subjects: 18
Study 29546554 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary titanium cranioplasty
Number of subjects: 64
Study 29546554 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone graft
Number of subjects: 64
Study 28490515 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (60 mg)
Number of subjects: 809
Study 28490515 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (14 other micronutrients)
Number of subjects: 809
Study 28490515 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus Multiple Micronutrients
Number of subjects: 809
Study 28490515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 26058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 15
Study 26058479 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 15
Study 26058479 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study 23416018 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LAmin volume
Number of subjects: 1159
Study 23416018 — intervention group
Group type: EXPERIMENTAL
Intervention: LAmin volume added to a model with classic risk factors for AF
Number of subjects: 1159
Study 23416018 — intervention group
Group type: EXPERIMENTAL
Intervention: LAmin volume compared to other LA measurements
Number of subjects: 1159
Study 23416018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox multivariable analysis
Number of subjects: 1159
Study 21700892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O₃) exposure (220 ppb)
Number of subjects: 138
Study 21700892 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 138